A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients

NCT01161368 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped poor recruitment

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Lapatinib, Vinorelbine

Sponsor

Central European Cooperative Oncology Group